Paramagnetic rim lesions (PRLs), which represent areas of damage in the brain and spinal cord with chronic active inflammation, are highly indicative of multiple sclerosis (MS) in people being evaluated for the disease, a new study reports. The findings support using this imaging biomarker as a useful tool for…
MRI lesions
Nearly two years of treatment with Vumerity (diroximel fumarate) significantly reduced relapse rates by more than 80% in people with relapsing-remitting multiple sclerosis (RRMS), according to the final published details of the EVOLVE-MS-1 clinical trial. MRI scans also showed the number of active inflammatory lesions and new…
Note: This story was updated Oct. 31, 2022, to correct that in the six months after treatment discontinuation, relapses were reported in 18.8% of RMMS patients and 3.5% of those with SPMS. When multiple sclerosis (MS) patients stop their disease-modifying treatment, the risk of relapses and disease activity on…
An extended interval between maintenance doses of Ocrevus (ocrelizumab) may increase the risk of MRI-based disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to a real-world, multicenter study in Italy. In fact, an extended interval dosing (by one month or longer) was associated with a fivefold higher risk…
Abnormalities detected on MRI scans at the onset and within the first two years of disease may predict disability worsening in children with multiple sclerosis (MS), a nine-year study reports. Specifically, damage in the spinal cord, brain, and optic nerve plays a major role in predicting outcomes in these…
Detecting changes to the brain’s central vein using common magnetic resonance imaging (MRI) scans is a useful and accurate strategy to enhance diagnosis of multiple sclerosis (MS), a new study shows. Analysis of more than 4,000 brain lesions, obtained from contrast-enhanced MRI scans collected from eight neuroimaging European…
A Phase 3 clinical trial evaluating the safety and effectiveness of ozanimod (RPC-1063) in patients with relapsing multiple sclerosis (RMS) shows treatment reduced the disease’s annualized relapse rate (ARR), researchers reported. The Phase 3 SUNBEAM trial (NCT02294058) tested ozanimod, an oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator designed to…
Researchers reported that patients with myelitis who later develop multiple sclerosis (MS) might be distinguished from others with myelitis by a number of characteristics, like the location and size of spinal cord lesions, a finding that might help clinicians diagnose MS and initiate treatment at an early stage. Myelitis, an…